Stories grouped for advocates—coverage fights, Medicare and drugs, FDA decisions, and federal billing policy.
Plan rules, prior authorization, Marketplace enrollment, and insurer policy shifts.
Insurers will be required to publish approval and denial rates by procedure starting January — a long-sought change from patient advocates.
By Jordan Reyes · 2h agoPart D, drug pricing, demonstrations, and Medicare program oversight.
CMS preview documents highlight insulin cap continuity, new MTM triggers, and stricter formulary change notice windows.
By Sam Okonkwo · YesterdayApproval paths, agency leadership, and repurposing or access debates.
Kyle Diamantas heard calls for clearer orphan-drug guidance, flexible trial designs, and stronger ties with rare disease communities.
By Morgan Ellis · TodayFederal initiatives, surprise billing, records access, and international pricing fights.
Federal IDR entities report staffing shortages; advocates warn patients may see delayed resolution on out-of-network bills.
By Morgan Ellis · 4h ago
